AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Uniphar PLC

AGM Information May 12, 2021

1951_dva_2021-05-12_57e37036-d06e-4862-9cd2-3f377cb96ea2.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 4280Y

Uniphar PLC

12 May 2021

AGM Results

Dublin, London | 12 May 2021

Uniphar plc is pleased to announce that at the Annual General Meeting held at 11.00 a.m. today, 12 May 2021, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment.

Details of votes cast are set out below:

RESOLUTION TOTAL FOR % AGAINST % ABSTAIN
1 Financial Statements and Reports 137,296,226 135,574,392 98.75 1,721,834 1.25 20,532
2 Final Dividend of €4.2m 137,296,226 137,293,095 100.00 3,131 0.00 20,532
3(a) Re-elect Tim Dolphin 137,316,758 137,242,840 99.95 73,918 0.05 0
3(b) Re-elect Padraic Dempsey 137,316,758 137,242,840 99.95 73,918 0.05 0
3(c) Re-elect Paul Hogan 137,316,758 136,410,522 99.34 906,236 0.66 0
3(d) Re-elect Maurice Pratt 137,316,758 137,219,247 99.93 97,511 0.07 0
4(a) Elect Jeff Berkowitz 137,316,758 137,284,424 99.98 32,334 0.02 0
4(b) Elect Jim Gaul 137,316,758 137,284,424 99.98 32,334 0.02 0
4(c) Elect Liz Hoctor 137,316,758 137,293,695 99.98 23,063 0.02 0
5 Remuneration of Auditors 125,264,944 119,641,181 95.51 5,623,763 4.49 12,051,814
6 Allot relevant securities 137,296,100 135,196,092 98.47 2,100,008 1.53 20,658
7 Disapplication of pre-emption rights in specified circumstances 137,264,600 137,241,537 99.98 23,063 0.02 52,158
8 Disapplication of pre-emption rights in additional circumstances 137,264,600 137,185,914 99.94 78,686 0.06 52,158
9 Authorise market purchases of the Company's Ordinary Shares 137,304,627 137,281,564 99.98 23,063 0.02 12,131
10 Re-issuance of Treasury Shares 137,304,627 137,281,564 99.98 23,063 0.02 12,131

--- ENDS ---

For further details contact:

Uniphar +353 (0) 1 428 7777
Brian O'Shaughnessy
Group Director of Corporate Development [email protected]
Davy +353 (0) 1 679 6363
(Joint Broker, Nominated Adviser and Euronext

Growth Adviser)
Fergal Meegan
Barry Murphy
Niall Gilchrist
RBC Capital Markets (Joint Broker) +44 (0) 20 7653 4000
Jonathan Hardy
Jamil Miah

Priyal Soni
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Matt Blawat
Ben Maddison
Francis North
Q4 PR +353 (0) 1 475 1444 or
(Public Relations Adviser to Uniphar) +353 87 235 6461
Iarla Mongey

About Uniphar plc

Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,600, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

Commercial & Clinical 

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, Benelux, the Nordics and the US, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by our highly experienced and clinically trained teams leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients. 

Product Access 

n Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

Supply Chain & Retail 

Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.330 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFLSEIIFLIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.